Impact of human papillomavirus vaccination on the clinical meaning of cervical screening results

Philip E. Castle, Xianhong Xie, Xiaonan (Nan) Xue, Nancy E. Poitras, Thomas S. Lorey, Walter K. Kinney, Nicolas Wentzensen, Howard Strickler, Emily A. Burger, Mark Schiffman

Research output: Contribution to journalArticle

Abstract

Women previously vaccinated against human papillomavirus (HPV) type 16 and 18 are now reaching the age (21 years) at which cervical-cancer screening is recommended in the U.S. The impact of HPV vaccination on risks of cervical precancer following a positive and negative screen among women aged 21–24 years who just started routine cervical screening are not well described. Therefore, three-year absolute and relative (RR) cumulative risks of cervical intraepithelial neoplasia grade 2 or more severe diagnoses (≥CIN2) and grade 3 or more severe diagnoses (≥CIN3) were estimated for women undergoing cervical screening at Kaiser Permanente Northern California. Risks were estimated in women aged 21–24 years (n = 75,008) undergoing cervical screening since late 2006, 6 months after HPV vaccination became available; women were categorized vaccinated at ages <18, 18–20, and 21–24 years and compared to those who were unvaccinated. Three-year risks were estimated for normal, low-grade, and high-grade cytology results. Three-year risks of ≥CIN2 and ≥CIN3 for unvaccinated women following low-grade cytology were 10.89% for and 3.70%, respectively. By comparison, Three-year risks of ≥CIN2 and ≥CIN3 were 5.26% (RR = 0.48, 95%CI = 0.24–0.99) and 0.99% (RR = 0.27, 95%CI = 0.06–1.13), respectively, for women vaccinated under the age of 18 years. Three-year ≥CIN2 and ≥CIN3 risks were lower for those HPV vaccinated at younger age for any screening result (ptrend ≤ 0.01 for all comparisons). These data support initiating cervical screening at an older age or changing the management of a low-grade cytology result in women aged 21–24 years who were vaccinated against HPV younger than age of 18 years.

LanguageEnglish (US)
Pages44-50
Number of pages7
JournalPreventive Medicine
Volume118
DOIs
StatePublished - Jan 1 2019

Fingerprint

Vaccination
Cell Biology
Human papillomavirus 18
Cervical Intraepithelial Neoplasia
Human papillomavirus 16
Early Detection of Cancer
Uterine Cervical Neoplasms

Keywords

  • Cervical precancer
  • Cytology
  • Human papillomavirus (HPV)
  • Screening
  • Vaccination

ASJC Scopus subject areas

  • Epidemiology
  • Public Health, Environmental and Occupational Health

Cite this

Impact of human papillomavirus vaccination on the clinical meaning of cervical screening results. / Castle, Philip E.; Xie, Xianhong; Xue, Xiaonan (Nan); Poitras, Nancy E.; Lorey, Thomas S.; Kinney, Walter K.; Wentzensen, Nicolas; Strickler, Howard; Burger, Emily A.; Schiffman, Mark.

In: Preventive Medicine, Vol. 118, 01.01.2019, p. 44-50.

Research output: Contribution to journalArticle

Castle, Philip E. ; Xie, Xianhong ; Xue, Xiaonan (Nan) ; Poitras, Nancy E. ; Lorey, Thomas S. ; Kinney, Walter K. ; Wentzensen, Nicolas ; Strickler, Howard ; Burger, Emily A. ; Schiffman, Mark. / Impact of human papillomavirus vaccination on the clinical meaning of cervical screening results. In: Preventive Medicine. 2019 ; Vol. 118. pp. 44-50.
@article{ecf924af56d244c5adc1bee86753c6d4,
title = "Impact of human papillomavirus vaccination on the clinical meaning of cervical screening results",
abstract = "Women previously vaccinated against human papillomavirus (HPV) type 16 and 18 are now reaching the age (21 years) at which cervical-cancer screening is recommended in the U.S. The impact of HPV vaccination on risks of cervical precancer following a positive and negative screen among women aged 21–24 years who just started routine cervical screening are not well described. Therefore, three-year absolute and relative (RR) cumulative risks of cervical intraepithelial neoplasia grade 2 or more severe diagnoses (≥CIN2) and grade 3 or more severe diagnoses (≥CIN3) were estimated for women undergoing cervical screening at Kaiser Permanente Northern California. Risks were estimated in women aged 21–24 years (n = 75,008) undergoing cervical screening since late 2006, 6 months after HPV vaccination became available; women were categorized vaccinated at ages <18, 18–20, and 21–24 years and compared to those who were unvaccinated. Three-year risks were estimated for normal, low-grade, and high-grade cytology results. Three-year risks of ≥CIN2 and ≥CIN3 for unvaccinated women following low-grade cytology were 10.89{\%} for and 3.70{\%}, respectively. By comparison, Three-year risks of ≥CIN2 and ≥CIN3 were 5.26{\%} (RR = 0.48, 95{\%}CI = 0.24–0.99) and 0.99{\%} (RR = 0.27, 95{\%}CI = 0.06–1.13), respectively, for women vaccinated under the age of 18 years. Three-year ≥CIN2 and ≥CIN3 risks were lower for those HPV vaccinated at younger age for any screening result (ptrend ≤ 0.01 for all comparisons). These data support initiating cervical screening at an older age or changing the management of a low-grade cytology result in women aged 21–24 years who were vaccinated against HPV younger than age of 18 years.",
keywords = "Cervical precancer, Cytology, Human papillomavirus (HPV), Screening, Vaccination",
author = "Castle, {Philip E.} and Xianhong Xie and Xue, {Xiaonan (Nan)} and Poitras, {Nancy E.} and Lorey, {Thomas S.} and Kinney, {Walter K.} and Nicolas Wentzensen and Howard Strickler and Burger, {Emily A.} and Mark Schiffman",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.ypmed.2018.10.001",
language = "English (US)",
volume = "118",
pages = "44--50",
journal = "Preventive Medicine",
issn = "0091-7435",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Impact of human papillomavirus vaccination on the clinical meaning of cervical screening results

AU - Castle, Philip E.

AU - Xie, Xianhong

AU - Xue, Xiaonan (Nan)

AU - Poitras, Nancy E.

AU - Lorey, Thomas S.

AU - Kinney, Walter K.

AU - Wentzensen, Nicolas

AU - Strickler, Howard

AU - Burger, Emily A.

AU - Schiffman, Mark

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Women previously vaccinated against human papillomavirus (HPV) type 16 and 18 are now reaching the age (21 years) at which cervical-cancer screening is recommended in the U.S. The impact of HPV vaccination on risks of cervical precancer following a positive and negative screen among women aged 21–24 years who just started routine cervical screening are not well described. Therefore, three-year absolute and relative (RR) cumulative risks of cervical intraepithelial neoplasia grade 2 or more severe diagnoses (≥CIN2) and grade 3 or more severe diagnoses (≥CIN3) were estimated for women undergoing cervical screening at Kaiser Permanente Northern California. Risks were estimated in women aged 21–24 years (n = 75,008) undergoing cervical screening since late 2006, 6 months after HPV vaccination became available; women were categorized vaccinated at ages <18, 18–20, and 21–24 years and compared to those who were unvaccinated. Three-year risks were estimated for normal, low-grade, and high-grade cytology results. Three-year risks of ≥CIN2 and ≥CIN3 for unvaccinated women following low-grade cytology were 10.89% for and 3.70%, respectively. By comparison, Three-year risks of ≥CIN2 and ≥CIN3 were 5.26% (RR = 0.48, 95%CI = 0.24–0.99) and 0.99% (RR = 0.27, 95%CI = 0.06–1.13), respectively, for women vaccinated under the age of 18 years. Three-year ≥CIN2 and ≥CIN3 risks were lower for those HPV vaccinated at younger age for any screening result (ptrend ≤ 0.01 for all comparisons). These data support initiating cervical screening at an older age or changing the management of a low-grade cytology result in women aged 21–24 years who were vaccinated against HPV younger than age of 18 years.

AB - Women previously vaccinated against human papillomavirus (HPV) type 16 and 18 are now reaching the age (21 years) at which cervical-cancer screening is recommended in the U.S. The impact of HPV vaccination on risks of cervical precancer following a positive and negative screen among women aged 21–24 years who just started routine cervical screening are not well described. Therefore, three-year absolute and relative (RR) cumulative risks of cervical intraepithelial neoplasia grade 2 or more severe diagnoses (≥CIN2) and grade 3 or more severe diagnoses (≥CIN3) were estimated for women undergoing cervical screening at Kaiser Permanente Northern California. Risks were estimated in women aged 21–24 years (n = 75,008) undergoing cervical screening since late 2006, 6 months after HPV vaccination became available; women were categorized vaccinated at ages <18, 18–20, and 21–24 years and compared to those who were unvaccinated. Three-year risks were estimated for normal, low-grade, and high-grade cytology results. Three-year risks of ≥CIN2 and ≥CIN3 for unvaccinated women following low-grade cytology were 10.89% for and 3.70%, respectively. By comparison, Three-year risks of ≥CIN2 and ≥CIN3 were 5.26% (RR = 0.48, 95%CI = 0.24–0.99) and 0.99% (RR = 0.27, 95%CI = 0.06–1.13), respectively, for women vaccinated under the age of 18 years. Three-year ≥CIN2 and ≥CIN3 risks were lower for those HPV vaccinated at younger age for any screening result (ptrend ≤ 0.01 for all comparisons). These data support initiating cervical screening at an older age or changing the management of a low-grade cytology result in women aged 21–24 years who were vaccinated against HPV younger than age of 18 years.

KW - Cervical precancer

KW - Cytology

KW - Human papillomavirus (HPV)

KW - Screening

KW - Vaccination

UR - http://www.scopus.com/inward/record.url?scp=85054796006&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054796006&partnerID=8YFLogxK

U2 - 10.1016/j.ypmed.2018.10.001

DO - 10.1016/j.ypmed.2018.10.001

M3 - Article

VL - 118

SP - 44

EP - 50

JO - Preventive Medicine

T2 - Preventive Medicine

JF - Preventive Medicine

SN - 0091-7435

ER -